Evidence map›Paper›PMID 39708330›Full record

ArticleJournal of cellular and molecular medicine2024

Deciphering the Significance of Platelet-Derived Chloride Ion Channel Gene (BEST3) Through Platelet-Related Subtypes Mining for Non-Small Cell Lung Cancer.

Hanxiao Ren, Meng-Ze Du, Yulin Liao, Ruiling Zu, Lubei Rao, Run Xiang, Xingmei Zhang, Shan Liu, Peiyin Zhang, Ping Leng and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hanxiao RenCollege of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People's Republic of China.ORCID 0009-0000-9003-9432
Meng-Ze DuSchool of Health and Medical Technology, Chengdu Neusoft University, Chengdu, Sichuan Province, People's Republic of China.
Yulin LiaoDepartment of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of the University of Electronic Science and Technology of China, Chengdu, China.
Ruiling ZuDepartment of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of the University of Electronic Science and Technology of China, Chengdu, China.
Lubei RaoDepartment of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of the University of Electronic Science and Technology of China, Chengdu, China.
Run XiangDepartment of Thoracic Surgery, Sichuan Cancer Hospital, Affiliate to the School of Medicine, The University of Electronic Science and Technology of China, Chengdu, China.
Xingmei ZhangCollege of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People's Republic of China.
Shan LiuCollege of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People's Republic of China.
Peiyin ZhangCollege of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People's Republic of China.
Ping LengCollege of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People's Republic of China.
Ling QiDepartment of Core Medical Laboratory, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China.ORCID 0000-0002-6275-3599
Huaichao LuoDepartment of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of the University of Electronic Science and Technology of China, Chengdu, China.

Funding

Natural Science Foundation of Sichuan Province 2024NSFSC1556WU JIEPING MEDICAL FOUNDATION 320.6750.2024-06-08
6 · The paper itself

Abstract

This study investigates platelet-related subtypes in non-small cell lung cancer (NSCLC) and seeks to identify genes associated with prognosis, focusing on the clinical significance of the chloride ion channel gene BEST3. We utilised sequencing and clinical data from GEO, TCGA and the Xena platform, building a risk model based on genetic features. TCGA and GSE37745 served as training cohorts, while GSE50081, GSE13213, GSE30129 and GSE42127 were validation cohorts. Immunotherapy datasets (GSE135222, TCGA-SKCM) were also analysed. Differentially expressed genes (DEGs) were identified using Limma, subtypes through ConsensusClusterPlus and key prognostic genes using COX regression, Random Forest and LASSO-COX. BEST3 expression was validated by flow cytometry (FCM) and functional assays in A549 cells with lentiviral overexpression evaluated its impact on apoptosis, proliferation and migration. Three platelet-related subtypes were identified, with ten key prognostic genes (including BEST3). Gene Ontology (GO) analysis showed six genes involved in platelet pathways. BEST3 was highly expressed in the platelet subtype 1. Flow cytometry confirmed elevated BEST3 levels in NSCLC (35.9% vs. 27.3% in healthy individuals). Overexpression of BEST3 in NSCLC cells suppressed apoptosis and promoted proliferation and migration. The discovery of three platelet subtypes and the role of BEST3 in promoting tumour growth and migration highlights its potential as a therapeutic target and prognostic marker in NSCLC.

Indexed as

Blood PlateletsCarcinoma, Non-Small-Cell LungChloride ChannelsGene Expression Regulation, NeoplasticLung NeoplasmsA549 CellsApoptosisBiomarkers, TumorCell MovementCell ProliferationDatabases, GeneticFemaleGene Expression ProfilingGene OntologyHumansMaleBiomarkers, TumorChloride ChannelsBEST3metastasisNSCLCplateletsprognosisproliferation

Identifiers

PMID39708330
PMCPMC11662966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.